Cytokinetics Announces Board Changes and Executive Compensation Updates
Ticker: CYTK · Form: 8-K · Filed: Apr 26, 2024 · CIK: 1061983
| Field | Detail |
|---|---|
| Company | Cytokinetics Inc (CYTK) |
| Form Type | 8-K |
| Filed Date | Apr 26, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.001, $550,000, $80,000, $1,682,500, $1,670,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: governance, executive-compensation, board-of-directors
TL;DR
Cytokinetics adds two directors and updates exec pay, including CEO Blum's deal.
AI Summary
On April 23, 2024, Cytokinetics, Incorporated announced changes in its board of directors and executive compensation. Specifically, Dr. Robert E. Conway and Ms. Mary Ann L. Lammie were elected to the Board of Directors. Additionally, the company entered into new employment agreements with certain officers, including an amended and restated employment agreement with its Chief Executive Officer, Robert I. Blum.
Why It Matters
These changes in leadership and compensation structure can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing primarily concerns routine corporate governance and executive compensation matters, with no immediate financial distress or significant operational changes indicated.
Key Players & Entities
- Cytokinetics, Incorporated (company) — Registrant
- Dr. Robert E. Conway (person) — Elected to Board of Directors
- Ms. Mary Ann L. Lammie (person) — Elected to Board of Directors
- Robert I. Blum (person) — Chief Executive Officer
FAQ
Who were the individuals elected to Cytokinetics' Board of Directors?
Dr. Robert E. Conway and Ms. Mary Ann L. Lammie were elected to the Board of Directors.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is April 23, 2024.
What is the principal executive office address for Cytokinetics, Incorporated?
The principal executive office is located at 350 Oyster Point Boulevard, South San Francisco, California 94080.
What type of agreements were entered into with certain officers?
The company entered into new employment agreements with certain officers, including an amended and restated employment agreement with its Chief Executive Officer, Robert I. Blum.
Under which section of the Securities Exchange Act of 1934 is this Current Report filed?
This Current Report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 1,600 words · 6 min read · ~5 pages · Grade level 12.8 · Accepted 2024-04-26 16:05:14
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CYTK The Nasdaq Global Se
- $550,000 — 's annual base salary will initially be $550,000, and he will be entitled to participate
- $80,000 — ee will also be paid a signing bonus of $80,000 which will be subject to repayment shou
- $1,682,500 — stock units with a grant date value of $1,682,500 (based on the closing price of the Comp
- $1,670,000 — stock units with a grant date value of $1,670,000 (based on the closing price of the Comp
Filing Documents
- cytk-20240423.htm (8-K) — 46KB
- 0000950170-24-049085.txt ( ) — 159KB
- cytk-20240423.xsd (EX-101.SCH) — 24KB
- cytk-20240423_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CYTOKINETICS, INCORPORATED Date: April 26, 2024 By: /s/ John O. Faurescu John O. Faurescu, Esq. VP, Associate General Counsel & Secretary